Biotech stocks Eledon (ELDN) and Acumen (ABOS) offer high-growth potential for long-term investors. Eledon focuses on immunology and organ transplantation, with a promising drug in trials. Acumen targets early Alzheimer’s disease with a monoclonal antibody. Both companies have upcoming clinical catalysts and positive analyst ratings, with significant upside potential.

Eledon Pharmaceuticals works on preventing organ transplant rejection and autoimmune diseases with a focus on immunomodulation. Positive trial results for tegoprubart, an anti-CD40L antibody, show promise in transplant immunosuppression. The company has ample cash reserves for operations and upcoming Phase 2 results for kidney transplantation in November 2025.

Acumen Pharmaceuticals concentrates on early Alzheimer’s treatment with sabirnetug, a humanized monoclonal antibody targeting toxic amyloid-beta oligomers. The company’s Phase 2 ALTITUDE-AD trial aims to assess the drug’s efficacy and safety, with anticipated results in late 2026. Acumen also collaborates on a blood-brain barrier-penetrating technology, J-Brain Cargo, to enhance drug delivery.

Read more at Yahoo Finance: 2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780%